Davda Sonal, Bezabeh Tedros
Institute for Biodiagnostics, National Research Council, 435 Ellice Avenue, Winnipeg, Manitoba, Canada, R3B 1Y6.
Cancer Metastasis Rev. 2006 Sep;25(3):469-80. doi: 10.1007/s10555-006-9009-z.
Tumor hypoxia and its downstream effects have remained of considerable interest for decades due to its negative impact on response to various cancer therapies and promotion of metastasis. Diagnosing hypoxia non-invasively can provide a significant advancement in cancer treatment and is the dire necessity for implementing specific targeted therapies now emerging to treat different aspects of cancer. A variety of techniques are being proposed to do so. However, none of them has yet been established in the clinical arena. This review summarizes the methods currently available to assess tumor hypoxia in vivo and their respective advantages and shortcomings. It also points out the impedances that need to be overcome to establish any particular method in the clinic, along with a broad overview of requirements for further advancement in this sphere of cancer research.
几十年来，肿瘤缺氧及其下游效应一直备受关注，因为它对各种癌症治疗的反应有负面影响，并促进转移。非侵入性诊断缺氧可为癌症治疗带来重大进展，也是实施目前正在出现的针对癌症不同方面的特定靶向治疗的迫切需要。为此人们提出了多种技术。然而，它们中尚无一种在临床领域得到确立。本综述总结了目前可用于体内评估肿瘤缺氧的方法及其各自的优缺点。它还指出了在临床中确立任何特定方法需要克服的障碍，以及对该癌症研究领域进一步发展的要求的大致概述。
